Acumen Pharmaceuticals, Inc.

NasdaqGS ABOS

Acumen Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 162.00 K

Acumen Pharmaceuticals, Inc. Gross Profit is USD 162.00 K for the Trailing 12 Months (TTM) ending September 30, 2024, a 183.51% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Acumen Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -194.00 K, a -57.72% change year over year.
Acumen Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -123.00 K, a 97.19% change year over year.
Acumen Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -4.38 M.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGS: ABOS

Acumen Pharmaceuticals, Inc.

CEO	Mr. Daniel J. O'Connell M.B.A.
IPO Date	July 1, 2021
Location	United States
Headquarters	427 Park Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Key trends

Past 5 years